Nexalin Technology (NXL) announced continued advancement toward its planned pivotal clinical trial evaluating HALO Clarity for the treatment of moderate to severe insomnia, designed to support Nexalin’s planned de novo submission to the U.S. Food and Drug Administration. The study is being conducted in collaboration with Lindus Health, a full-service clinical research organization engaged to oversee trial execution, regulatory preparation, and patient recruitment.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NXL:
- Nexalin announces continued advancement toward trial evaluating HALO Clarity
- Nexalin ‘commended’ recent Congressional initiative on neurostim research
- Nexalin Technology launches AI-designed virtual clinic platform NeuroCare
- Nexalin Technology highlights research validating neurostimulation technology
- Nexalin Faces Nasdaq Noncompliance Over Minimum Bid Price